Theratechnologies Inc. (TSE:TH) Forecasted to Earn FY2024 Earnings of $0.00 Per Share

Theratechnologies Inc. (TSE:TH) – Analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Theratechnologies in a research note issued to investors on Thursday, April 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of $0.00 for the year, up from their prior forecast of ($0.08). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Theratechnologies’ current full-year earnings is $0.04 per share.

Theratechnologies (TSE:TH) last announced its earnings results on Wednesday, February 21st. The company reported C($0.11) EPS for the quarter. Theratechnologies had a negative net margin of 29.30% and a negative return on equity of 1,116.86%. The firm had revenue of C$31.93 million for the quarter.

Theratechnologies Stock Performance

Shares of Theratechnologies stock opened at C$1.81 on Monday. The business has a 50-day moving average of C$1.99 and a 200 day moving average of C$2.10. Theratechnologies has a 12 month low of C$1.22 and a 12 month high of C$5.84. The stock has a market capitalization of C$83.22 million, a price-to-earnings ratio of -1.46, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. The company has a debt-to-equity ratio of 562.07, a current ratio of 1.34 and a quick ratio of 0.64.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.